Biopharma financing during the fourth quarter of 2023 totaled $13.1bn from 213 deals. Overall, there were 47 transactions meeting or exceeding $100m. The follow-on public offering (FOPO) category made up the greatest proportion (35%) of the aggregate Q4 financing dollars (see Exhibit 1), with 45 deals bringing in an aggregate $4.6bn.
Financing Quarterly Statistics, Q4 2023
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, October-December 2023
During the fourth quarter, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $1.1bn; while in vitro diagnostic firms and research tools players raised $459m.
